Gtx Inc., a Memphis, Tenn.-based company that has seen its shares (NASDAQ:GTXI) struggle ever since sharing disappointing results from a phase III study of enobosarm for muscle wasting in non-small-cell lung cancer patients in 2013, said it plans to meet the $1 minimum bid price requirement for continued listing on Nasdaq by effecting a reverse stock split, if necessary.